Palvella Therapeutics, Inc. PVLA 深 沪
已收盘 02-06 16:00:00 美东时间
82.20
+5.770
+7.55%
华盛通- 最 高85.045
- 今 开78.93
- 成交量 39.64万股
- 最 低 78.93
- 昨 收 76.43
- 总市值 9.73亿
- 52周最高 114.69
- 市盈率 静 --
- 换手率 3.35%
- 52周最低 17.31
- 委 比 50.92%
- 总股本 1183.65万
- 历史最高 114.69
- 量 比 1.03
- 振 幅 8.00%
- 历史最低 11.17
- 每 手 1
- 风险率 29.25%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Palvella Announces Publication Of Systematic Review In Clinical And Experimental Dermatology Which Synthesizes Available Published Clinical Evidence On Off-Label Statin Use For Cutaneous Application In Porokeratosis
Publication includes a systematic review of 24 studies describing off-label cutaneous application of statins in porokeratosisPreliminary case reports suggesting clinical benefit underscore unmet need for development of a
02-02 20:36
美股大行评级 | 潜在上涨空间31.6%！巴克莱上调台积电目标价至450美元；第一地平线全国银行获5家机构上调目标价
今日重点评级关注：Guggenheim：维持MBX Biosciences"买入"评级，目标价从77美元升至88美元；摩根士丹利：维持DraftKings"超配"评级，目标价从50美元升至53美元
01-20 10:26
BTIG Reiterates Buy on Palvella Therapeutics, Maintains $192 Price Target
BTIG analyst Jeet Mukherjee reiterates Palvella Therapeutics (NASDAQ:PVLA) with a Buy and maintains $192 price target.
01-17 01:26
美股大行评级 | 瑞银上调美光科技目标价从300美元升至400美元；Freedom上调百度目标价从120美元升至160美元
今日重点评级关注：Needham：维持Vaxcyte"买入"评级，目标价从90美元升至110美元；Citizens: 维持LGI Homes"跑赢大市"评级，目标价从85美元升至95美元
01-08 18:33
Mizuho Initiates Coverage On Palvella Therapeutics with Outperform Rating, Announces Price Target of $205
Mizuho analyst Graig Suvannavejh initiates coverage on Palvella Therapeutics (NASDAQ:PVLA) with a Outperform rating and announces Price Target of $205.
01-07 20:33
美股大行评级 | 潜在涨幅263.64%！Milestone Pharmaceuticals获富国银行升目标价至8美元，维持"超配"评级
今日重点评级关注：富国银行：维持Milestone Pharmaceuticals"超配"评级，目标价从4美元升至8美元；富国银行：维持Kyverna Therapeutics"超配"评级，目标价从31美元升至33美元
2025-12-17 10:46
美股大行评级 | 潜在涨幅113%！麦格理首予小马智行“跑赢大市"评级目标价29美元；Roth Capital下调好市多至"卖出"，目标价从906美元降至769美元
今日重点评级关注：HC Wainwright & Co.：维持BioCryst Pharma"买入"评级，目标价从30美元升至32美元；TD Cowen：上调Milestone Pharmaceuticals评级至"买入"，目标价8美元
2025-12-16 09:36
HC Wainwright & Co. Maintains Buy on Palvella Therapeutics, Raises Price Target to $200
HC Wainwright & Co. analyst Andrew S. Fein maintains Palvella Therapeutics (NASDAQ:PVLA) with a Buy and raises the price target from $190 to $200.
2025-12-16 02:12
Palvella: 73% Improved In Phase 2 Study Of Skin Condition Treatment
Palvella Therapeutics reports Phase 2 data showing 73% improvement with QTORIN rapamycin gel in cutaneous venous malformations.
2025-12-16 00:50
美股大行评级 | 高盛上调梅西百货目标价至22美元！ 摩根大通上调美国铝业公司目标价至45美元
今日重点评级关注：Stifel：维持X4 Pharmaceuticals"买入"评级，目标价从7.5美元升至10美元；花旗：维持UP Fintech Holding"买入"评级，目标价从17.4美元升至17.5美元
2025-12-08 08:34
